Recherche GCP Research

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes4 trials
• COPD2 trials
• Obesity2 trials
• Peripheral artery disease1 trial
• Type 1 diabetes1 trial

Phase

• Phase 34 trials
• Phase 23 trials

Status

• Completed5 trials
• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Novo Nordisk A/S3 trials
• Boehringer Ingelheim1 trial
• Expedition Therapeutics, Inc1 trial
• Hoffmann-La Roche1 trial
• Pfizer1 trial

Running trials

• Recruiting

  To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

  NCT07684820· Phase 2· Expedition Therapeutics, Inc· Source

  Contact: Diana Cimpean

• Active, not recruiting

  A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

  NCT07575932· Phase 2· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD1 recruiting

Closed trials

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06326047· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

  NCT05259033· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Novo Nordisk A/S· Source